IL126836A - Beta-inhibitor of protein kinase C beta-use for use as a drug for the treatment of eye diseases - Google Patents

Beta-inhibitor of protein kinase C beta-use for use as a drug for the treatment of eye diseases

Info

Publication number: IL126836A
Authority: IL; Israel
Prior art keywords: inhibitor; macular edema; protein kinase; related macular; isozyme
Prior art date: 1996-05-01

Application number

IL12683697A

Other languages

English (en)

Hebrew (he)

Other versions

IL126836A0 (en

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-01

Filing date

1997-05-01

Publication date

2004-05-12

1997-05-01 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1999-09-22 Publication of IL126836A0 publication Critical patent/IL126836A0/xx

2004-05-12 Publication of IL126836A publication Critical patent/IL126836A/en

Links

239000003112 inhibitor Substances 0.000 title claims abstract description 51
102000003923 Protein Kinase C Human genes 0.000 title claims abstract description 49
108090000315 Protein Kinase C Proteins 0.000 title claims abstract description 49
239000003814 drug Substances 0.000 title claims abstract description 17
208000022873 Ocular disease Diseases 0.000 title 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 50
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 50
208000001344 Macular Edema Diseases 0.000 claims abstract description 32
206010025415 Macular oedema Diseases 0.000 claims abstract description 30
201000010230 macular retinal edema Diseases 0.000 claims abstract description 30
238000011282 treatment Methods 0.000 claims abstract description 13
208000002780 macular degeneration Diseases 0.000 claims abstract description 10
208000014245 Ocular vascular disease Diseases 0.000 claims abstract description 8
241000124008 Mammalia Species 0.000 claims abstract description 7
210000001957 retinal vein Anatomy 0.000 claims abstract description 5
238000001356 surgical procedure Methods 0.000 claims abstract description 5
206010020772 Hypertension Diseases 0.000 claims abstract description 4
DQYBRTASHMYDJG-UHFFFAOYSA-N Bisindolylmaleimide Chemical group C1=CC=C2C(C=3C(=O)NC(C=3C=3C4=CC=CC=C4NC=3)=O)=CNC2=C1 DQYBRTASHMYDJG-UHFFFAOYSA-N 0.000 claims abstract 12
208000014882 Carotid artery disease Diseases 0.000 claims abstract 3
208000004644 retinal vein occlusion Diseases 0.000 claims abstract 3
208000007056 sickle cell anemia Diseases 0.000 claims abstract 3
208000007014 Retinitis pigmentosa Diseases 0.000 claims abstract 2
229940002612 prodrug Drugs 0.000 claims description 16
239000000651 prodrug Substances 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 16
125000000217 alkyl group Chemical group 0.000 claims description 14
108010044467 Isoenzymes Proteins 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 11
150000002148 esters Chemical class 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
229940123924 Protein kinase C inhibitor Drugs 0.000 claims description 7
239000003881 protein kinase C inhibitor Substances 0.000 claims description 7
101710175516 14 kDa zinc-binding protein Proteins 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims 5
150000002431 hydrogen Chemical group 0.000 claims 3
206010064930 age-related macular degeneration Diseases 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 claims 1
125000000539 amino acid group Chemical group 0.000 claims 1
125000003118 aryl group Chemical group 0.000 claims 1
125000002619 bicyclic group Chemical group 0.000 claims 1
239000001273 butane Substances 0.000 claims 1
125000001188 haloalkyl group Chemical group 0.000 claims 1
125000001475 halogen functional group Chemical group 0.000 claims 1
125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 47
230000002207 retinal effect Effects 0.000 description 31
210000002889 endothelial cell Anatomy 0.000 description 30
230000010261 cell growth Effects 0.000 description 20
238000000034 method Methods 0.000 description 18
230000012010 growth Effects 0.000 description 17
230000002792 vascular Effects 0.000 description 16
210000004027 cell Anatomy 0.000 description 14
230000000694 effects Effects 0.000 description 13
230000004856 capillary permeability Effects 0.000 description 12
239000000203 mixture Substances 0.000 description 12
230000000638 stimulation Effects 0.000 description 12
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 10
230000002401 inhibitory effect Effects 0.000 description 10
230000035699 permeability Effects 0.000 description 10
241000283690 Bos taurus Species 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
206010021143 Hypoxia Diseases 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000003102 growth factor Substances 0.000 description 8
230000001146 hypoxic effect Effects 0.000 description 8
239000002904 solvent Substances 0.000 description 8
238000002474 experimental method Methods 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
239000002609 medium Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000003511 endothelial effect Effects 0.000 description 6
210000003668 pericyte Anatomy 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 5
201000010099 disease Diseases 0.000 description 5
239000000975 dye Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
102000058223 human VEGFA Human genes 0.000 description 5
230000004044 response Effects 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
239000013543 active substance Substances 0.000 description 4
230000037396 body weight Effects 0.000 description 4
239000003636 conditioned culture medium Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
206010029113 Neovascularisation Diseases 0.000 description 3
229940123866 Protein kinase C beta inhibitor Drugs 0.000 description 3
241000700159 Rattus Species 0.000 description 3
208000017442 Retinal disease Diseases 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
244000309466 calf Species 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
-1 ester amide Chemical class 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
230000000302 ischemic effect Effects 0.000 description 3
229940098779 methanesulfonic acid Drugs 0.000 description 3
239000011707 mineral Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000012049 topical pharmaceutical composition Substances 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
230000004393 visual impairment Effects 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
206010002329 Aneurysm Diseases 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
206010058202 Cystoid macular oedema Diseases 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000009857 Microaneurysm Diseases 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
101710201186 Protein kinase C-like 1 Proteins 0.000 description 2
206010038923 Retinopathy Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
201000010206 cystoid macular edema Diseases 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
229940093499 ethyl acetate Drugs 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000003349 gelling agent Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002647 laser therapy Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
BQJRUJTZSGYBEZ-YVQNUNKESA-N phorbol 12,13-dibutanoate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCC)C1(C)C BQJRUJTZSGYBEZ-YVQNUNKESA-N 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000000790 retinal pigment Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 description 1
XPOKDUGZEKOMRB-UHFFFAOYSA-N 5-hydroxy-2-methylidenepentanoic acid Chemical compound OCCCC(=C)C(O)=O XPOKDUGZEKOMRB-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
241000220479 Acacia Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
208000005590 Choroidal Neovascularization Diseases 0.000 description 1
206010060823 Choroidal neovascularisation Diseases 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
206010012688 Diabetic retinal oedema Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100037362 Fibronectin Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
206010065630 Iris neovascularisation Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
102000015766 Protein Kinase C beta Human genes 0.000 description 1
108010024526 Protein Kinase C beta Proteins 0.000 description 1
208000007135 Retinal Neovascularization Diseases 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102100030859 Tissue factor Human genes 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
206010047531 Visual acuity reduced Diseases 0.000 description 1
206010047571 Visual impairment Diseases 0.000 description 1
CPGKMLVTFNUAHL-UHFFFAOYSA-N [Ca].[Ca] Chemical compound [Ca].[Ca] CPGKMLVTFNUAHL-UHFFFAOYSA-N 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
201000011190 diabetic macular edema Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000013534 fluorescein angiography Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000009545 invasion Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000013532 laser treatment Methods 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000011369 optimal treatment Methods 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000008807 pathological lesion Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
108091008695 photoreceptors Proteins 0.000 description 1
239000000049 pigment Substances 0.000 description 1
210000004694 pigment cell Anatomy 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000004250 retinal swelling Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000012058 sterile packaged powder Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
150000004684 trihydrates Chemical group 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
208000029257 vision disease Diseases 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL12683697A 1996-05-01 1997-05-01 Beta-inhibitor of protein kinase C beta-use for use as a drug for the treatment of eye diseases IL126836A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1665896P	1996-05-01	1996-05-01
US08/841,739 US6114320A (en)	1996-05-01	1997-04-30	Therapeutic treatment for VEGF related ocular diseases
PCT/US1997/007800 WO1997040831A1 (en)	1996-05-01	1997-05-01	Therapeutic treatment for vegf related occular diseases

Publications (2)

Publication Number	Publication Date
IL126836A0 IL126836A0 (en)	1999-09-22
IL126836A true IL126836A (en)	2004-05-12

Family

ID=26688915

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12683697A IL126836A (en)	1996-05-01	1997-05-01	Beta-inhibitor of protein kinase C beta-use for use as a drug for the treatment of eye diseases

Country Status (21)

Country	Link
US (1)	US6114320A (ru)
EP (1)	EP0918519B1 (ru)
JP (1)	JP4122060B2 (ru)
KR (1)	KR100364487B1 (ru)
CN (1)	CN1158073C (ru)
AT (1)	ATE270548T1 (ru)
AU (1)	AU724923B2 (ru)
BR (1)	BR9710705A (ru)
CA (1)	CA2253613C (ru)
CZ (1)	CZ296711B6 (ru)
DE (1)	DE69729798T2 (ru)
EA (1)	EA001752B1 (ru)
ES (1)	ES2224249T3 (ru)
HU (1)	HU226378B1 (ru)
IL (1)	IL126836A (ru)
NO (1)	NO322209B1 (ru)
NZ (2)	NZ538109A (ru)
PL (1)	PL189020B1 (ru)
PT (1)	PT918519E (ru)
UA (1)	UA54427C2 (ru)
WO (1)	WO1997040831A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5723456A (en) *	1993-12-07	1998-03-03	Eli Lilly & Company	Therapeutic treatment for cardiovascular diseases
US6093740A (en) *	1997-04-30	2000-07-25	Eli Lilly And Company	Therapeutic treatment for skin disorders
AU5733099A (en) *	1998-08-13	2000-03-06	Novartis Ag	Method for treating ocular neovascular diseases
US6214819B1 (en)	1998-11-23	2001-04-10	Novartis Ag	Method for treating ocular neovascular diseases
WO2000030651A1 (en) *	1998-11-23	2000-06-02	Novartis Ag	Use of staurosporine derivatives for treating ocular neovascular diseases
EP1140173B2 (en)	1998-12-22	2013-04-03	Genentech, Inc.	Vascular endothelial cell growth factor antagonists and uses thereof
US6271233B1 (en)	1999-08-10	2001-08-07	Ciba Vision Corporation	Method for treating ocular neovascular diseases
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
WO2001057008A1 (en)	2000-02-07	2001-08-09	Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft	2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
MXPA03008560A (es)	2001-03-22	2004-06-30	Abbot Gmbh & Co Kg	Pirazolopirimidinas como agentes terapeuticos.
US20020165158A1 (en) *	2001-03-27	2002-11-07	King George L.	Methods of modulating angiogenesis
US20030119812A1 (en) *	2001-11-08	2003-06-26	Brazzell Romulus Kimbro	Method for decreasing capillary permeability in the retina
US20030236246A1 (en) *	2002-04-30	2003-12-25	Brazzell Romulus Kimbro	Method for decreasing capillary permeability in the retina
EP2319493A3 (en) *	2002-07-23	2011-07-27	Novartis AG	Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
WO2004112796A1 (en) *	2003-06-20	2004-12-29	Alcon, Inc.	Treatment of amd with combination of ingredients
AU2005221283C1 (en) *	2004-03-17	2011-02-03	Lars Michael Larsen	Prevention of retinopathy by inhibition of the visual cycle
EP2308879A1 (en)	2004-04-02	2011-04-13	OSI Pharmaceuticals, Inc.	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
TW200613306A (en)	2004-07-20	2006-05-01	Osi Pharm Inc	Imidazotriazines as protein kinase inhibitors
AR057960A1 (es)	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
US7455447B2 (en) *	2006-05-19	2008-11-25	Mediatek Inc.	Method and apparatus for a portable device
JP2010501586A (ja) *	2006-08-23	2010-01-21	ノバルティスアクチエンゲゼルシャフト	眼疾患におけるｐｋｃ阻害剤、特にインドリルマレイミド誘導体の使用
WO2008042399A2 (en) *	2006-10-03	2008-04-10	The Trustees Of The University Of Pennsylvania	Method for treatment of macular degeneration
WO2016153877A1 (en) *	2015-03-26	2016-09-29	Eyekor, Llc	Image analysis
US20250115595A1 (en) *	2021-08-09	2025-04-10	The Johns Hopkins University	Inhibitors of hypoxia-inducible factors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ280738B6 (cs) *	1988-02-10	1996-04-17	F. Hoffmann - La Roche And Co., Aktiengesellschaft	Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DK0657411T3 (da) *	1993-12-07	1999-11-15	Lilly Co Eli	Forbedret syntese af bisindolylmaleimider
US5624949A (en) *	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
UA44690C2 (uk) *	1993-12-07	2002-03-15	Елі Ліллі Енд Компані	Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
US5545636A (en) *	1993-12-23	1996-08-13	Eli Lilly And Company	Protein kinase C inhibitors
US5481003A (en) *	1994-06-22	1996-01-02	Eli Lilly And Company	Protein kinase C inhibitors
US5491242A (en) *	1994-06-22	1996-02-13	Eli Lilly And Company	Protein kinase C inhibitors

1997
- 1997-01-05 UA UA98116304A patent/UA54427C2/ru unknown
- 1997-04-30 US US08/841,739 patent/US6114320A/en not_active Expired - Lifetime
- 1997-05-01 WO PCT/US1997/007800 patent/WO1997040831A1/en not_active Ceased
- 1997-05-01 NZ NZ538109A patent/NZ538109A/en not_active IP Right Cessation
- 1997-05-01 NZ NZ332833A patent/NZ332833A/en unknown
- 1997-05-01 KR KR10-1998-0708799A patent/KR100364487B1/ko not_active Expired - Fee Related
- 1997-05-01 EA EA199800970A patent/EA001752B1/ru not_active IP Right Cessation
- 1997-05-01 BR BR9710705A patent/BR9710705A/pt not_active Application Discontinuation
- 1997-05-01 PL PL97330463A patent/PL189020B1/pl not_active IP Right Cessation
- 1997-05-01 ES ES97923594T patent/ES2224249T3/es not_active Expired - Lifetime
- 1997-05-01 HU HU9902805A patent/HU226378B1/hu not_active IP Right Cessation
- 1997-05-01 AU AU29361/97A patent/AU724923B2/en not_active Ceased
- 1997-05-01 AT AT97923594T patent/ATE270548T1/de active
- 1997-05-01 PT PT97923594T patent/PT918519E/pt unknown
- 1997-05-01 CN CNB971956995A patent/CN1158073C/zh not_active Expired - Fee Related
- 1997-05-01 JP JP53929897A patent/JP4122060B2/ja not_active Expired - Fee Related
- 1997-05-01 EP EP97923594A patent/EP0918519B1/en not_active Expired - Lifetime
- 1997-05-01 CA CA002253613A patent/CA2253613C/en not_active Expired - Fee Related
- 1997-05-01 DE DE69729798T patent/DE69729798T2/de not_active Expired - Lifetime
- 1997-05-01 CZ CZ0349998A patent/CZ296711B6/cs not_active IP Right Cessation
- 1997-05-01 IL IL12683697A patent/IL126836A/en not_active IP Right Cessation
1998
- 1998-10-30 NO NO19985067A patent/NO322209B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
US6114320A (en)	2000-09-05
DE69729798D1 (de)	2004-08-12
EP0918519A1 (en)	1999-06-02
NO985067D0 (no)	1998-10-30
EP0918519B1 (en)	2004-07-07
EP0918519A4 (en)	1999-08-11
AU2936197A (en)	1997-11-19
CZ296711B6 (cs)	2006-05-17
HUP9902805A3 (en)	2000-04-28
ES2224249T3 (es)	2005-03-01
UA54427C2 (ru)	2003-03-17
NO322209B1 (no)	2006-08-28
NZ332833A (en)	2000-07-28
DE69729798T2 (de)	2005-08-25
WO1997040831A1 (en)	1997-11-06
PL189020B1 (pl)	2005-06-30
ATE270548T1 (de)	2004-07-15
CA2253613C (en)	2007-11-27
CA2253613A1 (en)	1997-11-06
NO985067L (no)	1998-12-22
PL330463A1 (en)	1999-05-24
CN1222850A (zh)	1999-07-14
KR100364487B1 (ko)	2003-01-25
HUP9902805A2 (hu)	2000-02-28
HK1020017A1 (en)	2000-03-10
CN1158073C (zh)	2004-07-21
EA199800970A1 (ru)	1999-06-24
AU724923B2 (en)	2000-10-05
JP4122060B2 (ja)	2008-07-23
BR9710705A (pt)	1999-08-17
IL126836A0 (en)	1999-09-22
KR20000065172A (ko)	2000-11-06
PT918519E (pt)	2004-10-29
JP2000514402A (ja)	2000-10-31
HU226378B1 (en)	2008-10-28
CZ349998A3 (cs)	1999-11-17
EA001752B1 (ru)	2001-08-27
NZ538109A (en)	2006-10-27

Publication	Publication Date	Title
IL126836A (en)	2004-05-12	Beta-inhibitor of protein kinase C beta-use for use as a drug for the treatment of eye diseases
WO1997040831A9 (en)	1998-02-19	Therapeutic treatment for vegf related occular diseases
AU2017326791B2 (en)	2022-11-17	Medicinal composition
KR20090010161A (ko)	2009-01-29	시클로리그난의 제2형 당뇨병의 치료를 위한, 그리고 피임약으로서의 용도
JP2018521120A (ja)	2018-08-02	翼状片を治療するための組成物及び方法
CN115768419A (zh)	2023-03-07	用于色满卡林前药治疗的改进方法和组合物
JP5363123B2 (ja)	2013-12-11	網膜神経又は視神経の保護剤
JP7636742B2 (ja)	2025-02-27	制御送達性クロマカリムプロドラッグ
KR20070040326A (ko)	2007-04-16	백내장, 황반 변성 및 다른 안과 질환의 개선
JP2024532015A (ja)	2024-09-04	徐放性クロマカリム療法用の組成物及び方法
AU2004255199A1 (en)	2005-01-20	Coumarin derivatives for the treatment of ophthalmic disorders
JP2012006918A (ja)	2012-01-12	イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤
WO2010056710A1 (en)	2010-05-20	Compositions and methods for treating eye diseases
HK1020017B (en)	2005-04-08	Therapeutic treatment for vegf related occular diseases
MXPA98009160A (en)	2000-05-01	Therapeutic treatment of ocular diseases related to the vascular endothelial growth factor (ve
JP2004528310A (ja)	2004-09-16	眼内圧を制御するためのプロペントフィリンの使用
AU2002250168A1 (en)	2002-10-08	Use of propentofylline to control intraocular pressure
ZA200604402B (en)	2008-03-26	Amelioration of cataracts, macular degeneration and other ophthalmic diseases

Legal Events

Date	Code	Title
2004-09-27	FF	Patent granted
2004-11-10	KB	Patent renewed
2007-07-06	KB	Patent renewed
2011-04-28	KB	Patent renewed
2015-12-31	MM9K	Patent not in force due to non-payment of renewal fees